Estrella Immunopharma (ESLA) Stock Chart & Stock Price History → Fidelity, Bezos, Goldman Bet Big on Tiny Biotech (From Behind the Markets) (Ad) Free ESLA Stock Alerts $1.05 +0.02 (+1.94%) (As of 10:06 AM ET) Add Compare Share Share ChartStock AnalysisChartCompetitorsEarningsFinancialsOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsOwnershipSEC FilingsShort InterestSocial Media Estrella Immunopharma Stock Price Performance5 Day Performance+5.00%1 Month Performance-4.55%3 Month Performance-8.70%6 Month Performance-21.64%Year-To-Date Performance-5.41% Receive ESLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Estrella Immunopharma and its competitors with MarketBeat's FREE daily newsletter Email Address Ad Behind the MarketsFidelity, Bezos, Goldman Bet Big on Tiny BiotechAre you ready for a major shift in the investment world? There's a new drug The Wall Street Journal is calling the "King Kong" of drugs.Don't miss out on the "next Ozempic" >>> ESLA Stock Chart for Wednesday, May, 8, 2024 ESLA Chart by TradingView Estrella Immunopharma Share Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization05/07/2024$1.00$1.03+3.00%$1.08$1.0015,219 shs$37.71 million05/06/2024$1.00$1.00$1.07$1.0011,477 shs$36.61 million05/03/2024$1.05$1.00-4.94%$1.08$1.0011,295 shs$36.61 million05/02/2024$1.05$1.05+0.19%$1.06$1.018,726 shs$38.51 million05/01/2024$1.05$1.05$1.09$1.0111,326 shs$38.44 million04/30/2024$1.07$1.05-1.78%$1.08$1.0119,522 shs$38.44 million Get the Latest News and Ratings for ESLA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Estrella Immunopharma and its competitors with MarketBeat's FREE daily newsletter. 04/29/2024$1.02$1.07+4.80%$1.08$1.0212,785 shs$39.14 million04/26/2024$1.04$1.02-1.92%$1.07$1.0214,309 shs$37.34 million04/25/2024$1.12$1.04-7.14%$1.07$1.041,119 shs$38.08 million04/24/2024$1.03$1.12+8.74%$1.12$1.0810,206 shs$41.00 million04/23/2024$1.07$1.03-3.29%$1.08$1.031,273 shs$37.71 million04/22/2024$1.07$1.07-0.47%$1.12$1.063,797 shs$38.99 million04/19/2024$1.03$1.07+3.88%$1.07$0.998,938 shs$39.17 million04/18/2024$1.12$1.03-8.04%$1.13$1.0062,213 shs$37.71 million04/17/2024$1.09$1.12+3.23%$1.12$1.033,869 shs$41.00 million04/16/2024$1.06$1.09+2.36%$1.14$1.022,932 shs$39.72 million04/15/2024$1.13$1.06-6.19%$1.22$1.0616,675 shs$38.81 million04/12/2024$1.09$1.13+3.67%$1.13$1.102,971 shs$41.37 million04/11/2024$1.15$1.09-5.22%$1.17$1.0827,948 shs$39.91 million04/10/2024$1.10$1.15+4.55%$1.20$1.0718,219 shs$42.10 million04/09/2024$1.10$1.10$1.21$1.0620,981 shs$40.27 million04/08/2024$1.15$1.10-4.35%$1.21$1.1024,152 shs$40.27 million04/05/2024$1.14$1.15+0.88%$1.16$1.082,247 shs$42.10 million04/04/2024$1.22$1.14-6.55%$1.21$1.0721,762 shs$41.74 million04/03/2024$1.23$1.22-0.82%$1.22$1.1118,500 shs$44.66 million04/02/2024$1.26$1.23-2.38%$1.27$1.106,152 shs$45.03 million04/01/2024$1.24$1.26+1.61%$1.31$1.1633,769 shs$46.13 million03/29/2024$1.24$1.24$1.26$1.2020,903 shs$45.40 million03/28/2024$1.25$1.24-0.80%$1.26$1.2020,902 shs$45.40 million03/27/2024$1.26$1.25-0.76%$1.25$1.0827,869 shs$45.76 million03/26/2024$1.13$1.26+11.47%$1.26$1.1643,264 shs$46.12 million03/25/2024$1.15$1.13-1.74%$1.15$1.125,672 shs$41.37 million03/22/2024$1.08$1.15+6.48%$1.18$1.063,875 shs$42.10 million03/21/2024$1.04$1.08+3.84%$1.25$1.0355,105 shs$39.54 million03/20/2024$1.10$1.04-5.45%$1.11$1.0418,458 shs$38.08 million03/19/2024$1.10$1.10$1.13$1.0818,986 shs$40.27 million03/18/2024$1.11$1.10-0.90%$1.15$1.0810,115 shs$40.27 million03/15/2024$1.03$1.11+7.77%$1.14$1.0333,018 shs$40.64 million03/14/2024$1.10$1.03-6.36%$1.12$1.0352,364 shs$37.71 million03/13/2024$1.19$1.10-7.56%$1.19$1.0673,187 shs$40.27 millionBREAKING – Pentagon to Spend $20 Billion on “Distributed AI” (Ad)BREAKING - Pentagon to Spend $20 Billion on "Distributed AI" The U.S. Space Force calls it a "game changer." And one tiny firm is poised to win the contract to build it.Discover the name and ticker of this $2 stock here >>>03/12/2024$0.98$1.19+21.43%$1.40$0.98372,650 shs$43.57 million03/11/2024$1.04$0.98-5.77%$1.06$0.9678,762 shs$35.88 million03/08/2024$1.07$1.04-2.79%$1.16$1.0081,578 shs$38.07 million03/07/2024$1.13$1.07-5.32%$1.17$0.9584,239 shs$39.17 million03/06/2024$1.01$1.13+11.88%$1.20$0.92119,331 shs$41.37 million03/05/2024$1.01$1.01$1.03$0.9615,504 shs$36.98 million03/04/2024$1.07$1.01-5.16%$1.08$0.8632,278 shs$36.98 million03/01/2024$1.02$1.07+4.41%$1.09$1.0216,740 shs$38.99 million02/29/2024$1.01$1.02+0.99%$1.08$1.0123,056 shs$37.34 million02/28/2024$1.04$1.01-2.88%$1.07$1.0110,963 shs$36.98 million02/27/2024$1.06$1.04-1.89%$1.16$1.0215,752 shs$38.07 million02/26/2024$1.01$1.06+4.95%$1.14$1.0324,491 shs$38.81 million02/23/2024$1.01$1.01$1.17$1.0113,737 shs$36.98 million02/22/2024$1.04$1.01-2.88%$1.08$1.0117,070 shs$36.98 million02/21/2024$1.06$1.04-1.89%$1.11$1.0313,372 shs$38.07 million02/20/2024$1.10$1.06-3.64%$1.10$1.0313,049 shs$38.81 million02/19/2024$1.10$1.10$1.17$1.0534,300 shs$40.27 million02/16/2024$1.09$1.10+0.92%$1.17$1.0534,316 shs$38.72 million02/15/2024$1.08$1.09+0.93%$1.16$1.0916,275 shs$38.37 million02/14/2024$1.14$1.08-5.26%$1.38$1.0830,046 shs$38.02 million02/13/2024$1.11$1.14+2.70%$1.21$1.128,837 shs$40.13 million02/12/2024$1.16$1.11-4.31%$1.22$1.1110,049 shs$39.07 million02/09/2024$1.15$1.16+0.86%$1.25$1.0383,259 shs$40.83 million02/08/2024$1.19$1.15-3.35%$1.25$1.1019,186 shs$40.48 million02/07/2024$1.24$1.19-4.03%$1.25$1.1112,122 shs$41.89 million Related Companies: SAB Biotherapeutics Stock Chart Dyadic International Stock Chart Cyclo Therapeutics Stock Chart NKGen Biotech Stock Chart Surrozen Stock Chart MiNK Therapeutics Stock Chart Protara Therapeutics Stock Chart OKYO Pharma Stock Chart IN8bio Stock Chart Cortexyme Stock Chart Receive ESLA Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Estrella Immunopharma and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:ESLA) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorFidelity, Bezos, Goldman Bet Big on Tiny BiotechBehind the MarketsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaAI “wealth window” is closing June 25thParadigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressGold Set to EXPLODE!Gold Safe ExchangeThe AI Stock that’s Disrupting Every IndustryStockEarningsThe #1 lithium battery stock to have on your radar in 2024!Smallcaps Daily Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.